Hyperglycemia and PPARγ antagonistically influence macrophage polarization and infarct healing after ischemic stroke

Stroke

Volumn 46, Issue 10, 2015, Pages 2935-2942

  Gliem, Michael ^a   Klotz, Luisa ^b   Van Rooijen, Nico ^c   Hartung, Hans Peter ^a   Jander, Sebastian ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Anticoagulation; Cerebral ischemia; Inflammation; Intracerebral hemorrhage; Macrophage

Indexed keywords

B7 ANTIGEN; CD11B ANTIGEN; CD45 ANTIGEN; COLLAGEN TYPE 4; GLUCOSE; INTERLEUKIN 10; INTERLEUKIN 1BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENPROCOUMON; PIOGLITAZONE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; AUTACOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE MARROW CELL; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CELL DIFFERENTIATION; GENE INACTIVATION; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; INTERNATIONAL NORMALIZED RATIO; MACROPHAGE; MIDDLE CEREBRAL ARTERY OCCLUSION; MONOCYTE; MOUSE; NONHUMAN; PHENOTYPE; POLARIZATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK FACTOR; SECONDARY INTRACEREBRAL HEMORRHAGE; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; VASCULAR REMODELING; AGONISTS; ANGIOGENESIS; ANIMAL; CELL POLARITY; CEREBRAL ARTERY DISEASE; CHEMICALLY INDUCED; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; INFLAMMATION; KNOCKOUT MOUSE; PATHOPHYSIOLOGY;

ANIMALS; ANTICOAGULANTS; CELL POLARITY; CEREBRAL HEMORRHAGE; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INFARCTION, MIDDLE CEREBRAL ARTERY; INFLAMMATION; INFLAMMATION MEDIATORS; MACROPHAGES; MICE; MICE, KNOCKOUT; MONOCYTES; NEOVASCULARIZATION, PHYSIOLOGIC; PHENPROCOUMON; PPAR GAMMA; RISK FACTORS; THIAZOLIDINEDIONES; VASCULAR REMODELING;

EID: 84942856373     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.010557     Document Type: Article

References (43)

1. Hart RG, Coull BM, Hart D. Early recurrent embolism associated with nonvalvular atrial fbrillation: a retrospective study. Stroke. 1983;14:688-693. doi: 10.1161/01.STR.14.5.688.
2. Cardiogenic brain embolism. Cerebral Embolism Task Force. Arch Neurol. 1986;43:71-84.
3. Yasaka M, Yamaguchi T, Oita J, Sawada T, Shichiri M, Omae T. Clinical features of recurrent embolization in acute cardioembolic stroke. Stroke. 1993;24:1681-1685. doi: 10.1161/01.STR.24.11.1681.
4. Sacco RL, Shi T, Zamanillo MC, Kargman DE. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology. 1994;44:626-634.
5. Arboix A, García-Eroles L, Oliveres M, Massons JB, Targa C. Clinical predictors of early embolic recurrence in presumed cardioembolic stroke. Cerebrovasc Dis. 1998;8:345-353.
6. Arboix A, Alió J. Cardioembolic stroke: clinical features, specifc cardiac disorders and prognosis. Curr Cardiol Rev. 2010;6:150-161. doi: 10.2174/157340310791658730.
7. Hankey GJ. Unanswered questions and research priorities to optimise stroke prevention in atrial fbrillation with the new oral anticoagulants. Thromb Haemost. 2014;111:808-816. doi: 10.1160/TH13-09-0741.
8. Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci. 2003;4:399-415. doi: 10.1038/nrn1106.
9. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med. 2011;17:796-808. doi: 10.1038/nm.2399.
10. Gelderblom M, Leypoldt F, Steinbach K, Behrens D, Choe CU, Siler DA, et al. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke. 2009;40:1849-1857. doi: 10.1161/STROKEAHA.108.534503.
11. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 2003;19:71-82.
12. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5:953-964. doi: 10.1038/nri1733.
13. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med. 2007;204:3037-3047. doi: 10.1084/jem.20070885.
14. Arnold L, Henry A, Poron F, Baba-Amer Y, van Rooijen N, Plonquet A, et al. Infammatory monocytes recruited after skeletal muscle injury switch into antiinfammatory macrophages to support myogenesis. J Exp Med. 2007;204:1057-1069. doi: 10.1084/jem.20070075.
15. Hilgendorf I, Gerhardt LM, Tan TC, Winter C, Holderried TA, Chousterman BG, et al. Ly-6Chigh monocytes depend on Nr4a1 to balance both infammatory and reparative phases in the infarcted myocardium. Circ Res. 2014;114:1611-1622. doi: 10.1161/CIRCRESAHA.114.303204.
16. Gliem M, Mausberg AK, Lee JI, Simiantonakis I, van Rooijen N, Hartung HP, et al. Macrophages prevent hemorrhagic infarct transformation in murine stroke models. Ann Neurol. 2012;71:743-752. doi: 10.1002/ana.23529.
17. Gliem M, Hermsen D, van Rooijen N, Hartung HP, Jander S. Secondary intracerebral hemorrhage due to early initiation of oral anticoagulation after ischemic stroke: an experimental study in mice. Stroke. 2012;43:3352-3357. doi: 10.1161/STROKEAHA.112.666818.
18. Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I. Increased monocytic activity and biomarkers of infammation in patients with type 1 diabetes. Diabetes. 2006;55:774-779.
19. Panizzi P, Swirski FK, Figueiredo JL, Waterman P, Sosnovik DE, Aikawa E, et al. Impaired infarct healing in atherosclerotic mice with Ly-6C(hi) monocytosis. J Am Coll Cardiol. 2010;55:1629-1638. doi: 10.1016/j. jacc.2009.08.089.
20. Mirza R, Koh TJ. Dysregulation of monocyte/macrophage phenotype in wounds of diabetic mice. Cytokine. 2011;56:256-264. doi: 10.1016/j. cyto.2011.06.016.
21. Al-Mulla F, Leibovich SJ, Francis IM, Bitar MS. Impaired TGF-|3 signaling and a defect in resolution of infammation contribute to delayed wound healing in a female rat model of type 2 diabetes. Mol Biosyst. 2011;7:3006-3020. doi: 10.1039/c0mb00317d.
22. Demchuk AM, Morgenstern LB, Krieger DW, Linda Chi T, Hu W, Wein TH, et al. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke. 1999;30:34-39. doi: 10.1161/01.STR.30.1.34.
23. Paciaroni M, Agnelli G, Corea F, Ageno W, Alberti A, Lanari A, et al. Early hemorrhagic transformation of brain infarction: rate, predictive factors, and infuence on clinical outcome: results of a prospective multicenter study. Stroke. 2008;39:2249-2256. doi: 10.1161/STROKEAHA.107.510321.
24. Ahmed N, Dávalos A, Eriksson N, Ford GA, Glahn J, Hennerici M, et al; SITS Investigators. Association of admission blood glucose and outcome in patients treated with intravenous thrombolysis: results from the Safe Implementation of Treatments in Stroke International Stroke Thrombolysis Register (SITS-ISTR). Arch Neurol. 2010;67:1123-1130. doi: 10.1001/archneurol.2010.210.
25. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, Mukundan L, et al. Macrophage-specifc PPARgamma controls alternative activation and improves insulin resistance. Nature. 2007;447:1116-1120. doi: 10.1038/nature05894.
26. Hucke S, FloBdorf J, Grützke B, Dunay IR, Frenzel K, Jungverdorben J, et al. Licensing of myeloid cells promotes central nervous system autoimmunity and is controlled by peroxisome proliferator-activated receptor y. Brain. 2012;135(pt 5):1586-1605. doi: 10.1093/brain/aws058.
27. Bauer J, Huitinga I, Zhao W, Lassmann H, Hickey WF, Dijkstra CD. The role of macrophages, perivascular cells, and microglial cells in the pathogenesis of experimental autoimmune encephalomyelitis. Glia. 1995;15:437-446. doi: 10.1002/glia.440150407.
28. Bruno A, Levine SR, Frankel MR, Brott TG, Lin Y, Tilley BC, et al; NINDS rt-PA Stroke Study Group. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology. 2002;59:669-674.
29. Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM, et al. Major bleeding in patients with atrial fbrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol. 2014;63:2141-2147. doi: 10.1016/j.jacc.2014.02.549.
30. Jickling GC, Liu D, Stamova B, Ander BP, Zhan X, Lu A, et al. Hemorrhagic transformation after ischemic stroke in animals and humans. J Cereb Blood Flow Metab. 2014;34:185-199. doi: 10.1038/jcbfm.2013.203.
31. Vats D, Mukundan L, Odegaard JI, Zhang L, Smith KL, Morel CR, et al. Oxidative metabolism and PGC-1beta attenuate macrophage-mediated infammation. Cell Metab. 2006;4:13-24. doi: 10.1016/j.cmet.2006.05.011.
32. Rodríguez-Prados JC, Través PG, Cuenca J, Rico D, Aragonés J, Martín-Sanz P, et al. Substrate fate in activated macrophages: a comparison between innate, classic, and alternative activation. J Immunol. 2010;185:605-614. doi: 10.4049/jimmunol.0901698.
33. Galván-Peña S, O'Neill LA. Metabolic reprograming in macrophage polarization. Front Immunol. 2014;5:420. doi: 10.3389/fmmu.2014.00420.
34. Kernan WN, Inzucchi SE, Viscoli CM, Brass LM, Bravata DM, Shulman GI, et al. Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke. Stroke. 2003;34:1431-1436. doi: 10.1161/01.STR.0000071108.00234.0E.
35. Sundararajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD, Landreth GE. Peroxisome proliferator-activated receptor-gamma ligands reduce infammation and infarction size in transient focal ischemia. Neuroscience. 2005;130:685-696. doi: 10.1016/j. neuroscience.2004.10.021.
36. Luo Y, Yin W, Signore AP, Zhang F, Hong Z, Wang S, et al. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J Neurochem. 2006;97:435-448. doi: 10.1111/j.1471-4159.2006.03758.x.
37. Zhao X, Strong R, Zhang J, Sun G, Tsien JZ, Cui Z, et al. Neuronal PPARgamma defciency increases susceptibility to brain damage after cerebral ischemia. J Neurosci. 2009;29:6186-6195. doi: 10.1523/JNEUROSCI.5857-08.2009.
38. Zhao X, Sun G, Zhang J, Strong R, Song W, Gonzales N, et al. Hematoma resolution as a target for intracerebral hemorrhage treatment: role for peroxisome proliferator-activated receptor gamma in microglia/macrophages. Ann Neurol. 2007;61:352-362. doi: 10.1002/ana.21097.
39. Zhao XR, Gonzales N, Aronowski J. Pleiotropic role of PPARy in intracerebral hemorrhage: an intricate system involving Nrf2, RXR, and NF-KB. CNS Neurosci Ther. 2015;21:357-366. doi: 10.1111/cns.12350.
40. Liu J, Gao BB, Clermont AC, Blair P, Chilcote TJ, Sinha S, et al. Hyperglycemia-induced cerebral hematoma expansion is mediated by plasma kallikrein. Nat Med. 2011;17:206-210. doi: 10.1038/nm.2295.
41. Nieswandt B, Stoll G. Sugar rush bleeds the brain. Nat Med. 2011;17:161-162. doi: 10.1038/nm0211-161.
42. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122:787-795. doi: 10.1172/JCI59643.
43. Rahman M, Muhammad S, Khan MA, Chen H, Ridder DA, Müller-Fielitz H, et al. The |3-hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages. Nat Commun. 2014;5:3944. doi: 10.1038/ncomms4944.